Drug intelligence / Profile preview

GL-12

Development stage: Preclinical
Lead developer: New York University

Overview

GL-12 is an investigational drug initially developed by New York University, currently in the preclinical stage of research. It is being studied primarily for cardiovascular diseases. The exact drug type and mechanism of action are not publicly detailed, but it is associated with therapeutic areas related to cardiovascular conditions. The development involves New York University and Xentria, Inc., which also hold licensing rights. No clinical trial results or approval status beyond preclinical have been reported as of May 2025.

Other names: GL-12GL12GL 12

Beyond the preview

Go deeper on GL-12.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GL-12.

Explore the full profile